The Federal Trade Commission reached a deal with Amgen Inc. to approve its $27.8 billion acquisition of Horizon Therapeutics plc, the agency announced...
The Federal Trade Commission reached a deal with Amgen Inc. AMGN, -0.60% to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP, -0.07% the agency announced Friday.
Under the deal. Amgen will be barred from bundling existing products with Horizon’s Tepezza or Krystexxa, two drugs used to treat thyroid eye disease and chronic refractory gout, respectively.As part of the deal, attorneys general for California, Illinois, Minnesota, New York, Washington, and Wisconsin have also agreed to dismiss their federal suits seeking to block the merger.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisitionThe FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would 'stifle competition' in the pharmaceutical industry.
続きを読む »
U.S. FTC allows Amgen to go ahead with $27.8 bln Horizon dealThe U.S. Federal Trade Commission has allowed drugmaker Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics HZNP.O, the companies said on Friday, dropping its earlier objections to the deal.
続きを読む »
U.S. FTC allows Amgen to go ahead with $27.8 billion Horizon deal By ReutersU.S. FTC allows Amgen to go ahead with $27.8 billion Horizon deal
続きを読む »
Sage Therapeutics to cut 40% of jobs after depression drug setback By ReutersSage Therapeutics to cut 40% of jobs after depression drug setback
続きを読む »
As Huntsville moves to increase water rate, another hike may be on the horizonThe City of Huntsville is considering rate changes for its solid waste collection system.
続きを読む »